These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 3000280)

  • 1. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
    Ruberg M; Javoy-Agid F; Hirsch E; Scatton B; LHeureux R; Hauw JJ; Duyckaerts C; Gray F; Morel-Maroger A; Rascol A
    Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
    Kish SJ; Chang LJ; Mirchandani L; Shannak K; Hornykiewicz O
    Ann Neurol; 1985 Nov; 18(5):530-6. PubMed ID: 2416269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
    Bokobza B; Ruberg M; Scatton B; Javoy-Agid F; Agid Y
    Eur J Pharmacol; 1984 Mar; 99(2-3):167-75. PubMed ID: 6734727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
    Garvey J; Petersen M; Waters CM; Rose SP; Hunt S; Briggs R; Jenner P; Marsden CD
    Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive supranuclear palsy: postmortem chemical analysis.
    Young AB
    Ann Neurol; 1985 Nov; 18(5):521-2. PubMed ID: 2866753
    [No Abstract]   [Full Text] [Related]  

  • 6. Brain neurotransmitters and neuropeptides in Parkinson's disease.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
    Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
    Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
    Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal dopamine deficiency in Parkinson's disease: role of aging.
    Scherman D; Desnos C; Darchen F; Pollak P; Javoy-Agid F; Agid Y
    Ann Neurol; 1989 Oct; 26(4):551-7. PubMed ID: 2817829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical neurotransmission in the parkinsonian brain.
    Rinne UK; Rinne JO; Rinne JK; Laakso K
    Med Biol; 1987; 65(2-3):75-81. PubMed ID: 2821331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of selective lesions of cholinergic and dopaminergic neurons on serotonin-type 1 receptors in rat brain.
    Quirion R; Richard J
    Synapse; 1987; 1(1):124-30. PubMed ID: 3145578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine and homovanillic acid concentrations in striatal and limbic regions of human brain.
    Walsh FX; Stevens TJ; Langlais PJ; Bird ED
    Ann Neurol; 1982 Jul; 12(1):52-5. PubMed ID: 7114818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
    Melamed E; Hefti F; Wurtman RJ
    Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
    Ahlskog JE; Richelson E; Nelson A; Kelly PJ; Okazaki H; Tyce GM; van Heerden JA; Stoddard SL; Carmichael SW
    Ann Neurol; 1991 Aug; 30(2):185-91. PubMed ID: 1654766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Tong J; Fitzmaurice PS; Ang LC; Furukawa Y; Guttman M; Kish SJ
    Ann Neurol; 2004 Jan; 55(1):125-9. PubMed ID: 14705122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.